The demonstrated antineoplastic activity of a retinoid in combination with an HMA has implications beyond myeloid malignancies, i.e., also in frequent solid tumor entities, particularly those with a high incidence of TP53 mutations, such as triple-negative breast cancer and pancreatic cancer. Here, TP53 is linked to triple-negative breast carcinoma.